Fig 2: The relationship of POLD1 expression with marker gene sets of immune cells, immunomodulators and chemokines. (A–C) The bubble plot shows the association of the POLD1 gene with the marker sets of 16 diverse immune cells or their status (A); markers of immunomodulators (B); as well as markers of chemokines/chemokine receptors (C).

Fig 3: Characteristics of immune cell infiltration in tumors with POLD1 expression. (A,B) The relationship between POLD1 expression and immune cell infiltrates was analyzed by the xCell (A) and TISIDB (B) platforms. (C) Proportions of 22 immune cells in the subgroups (POLD1high and POLD1low) of ccRCC. (D) The tumor immune microenvironment (TME) scores between the POLD1high and POLD1low groups (including stromal score, immune score, and estimate score). (E) Differences in the activities of diverse immune cells between the POLD1high and POLD1low groups. (F) Analysis of the activity of pro-tumor suppression and anti-tumor immunity in the POLD1high and POLD1low groups. ns, No significance, * p < 0.05, ** p < 0.01, *** p < 0.001.

Fig 4: The association between POLD1 expression and anticancer drug sensitivity. (A) TIDE score, MSI, T cell Dysfunction and Exclusion in different POLD1 expression groups. (B) Gene-set drug-resistance analysis from GDSC and CTRP IC50 drug data. Spearman’s correlation represents an association between gene expression and the drug. A positive association (red bubbles) means that high gene expression confers resistance to the drug, and a negative one (blue bubbles) means it does not. ns, No significance, * p < 0.05, ** p < 0.01, *** p < 0.001.

Fig 5: Association between POLD1 expression and the clinical parameters of ccRCC patients and its prognostic significance. (A–D) Relationship of POLD1 mRNA levels with individual cancer stages (T stage, N stage and M stage) and tumor grade of ccRCC patients. (E–G) Relationship of POLD1 expression levels with overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) in the TCGA-KIRC cohort. (H,I) Univariate and multivariate survival analyses for selecting prognostic factors. (J,K) Establishment (J) and estimate (K) of the overall survival nomogram for ccRCC patients.